D-0508-2023 Class II Ongoing

Recalled by Direct Rx — Dawsonville, GA

FDA drug recall D-0508-2023 was initiated by Direct Rx on Mar 22, 2023 and is designated Class II. Reason for recall: CGMP Deviations: Repackaging firm recalling due to potential product cross contamination concerns at the manufacturer. The recall status is ongoing. Affected quantity: 349 bottles.

Recall details

Product Type
Drugs
Report Date
Apr 12, 2023
Initiation Date
Mar 22, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
349 bottles

Product description

Alprazolam C-IV, 1 mg, packaged in a) 30 Tabs per bottle, NDC 72189-213-30; b) 60 Tabs per bottle, NDC 72189-213-60; Rx only, Packaged and Distributed By: Direct Rx Dawsonville, GA 30534.

Reason for recall

CGMP Deviations: Repackaging firm recalling due to potential product cross contamination concerns at the manufacturer.

Distribution pattern

Nationwide in the USA

Code information

Lots: a) 03FE2318, Exp. 8/31/24; b) 27FE2315, 28FE2313, 02MA2306, 21SE2201, 16NO2216, 17NO2216, 24FA2314, Exp. 8/31/24; 17FE2203, 12AP2204, 17MA2205, Exp. 3/31/23; 21JU2206, 22JU2220, 12JY2206, Exp. 5/31/23; 10AU2209, Exp. 6/30/23; 14DE2215, Exp. 9/30/24; 05JA2304, 27JA2301, Exp. 11/30/24.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0508-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0508-2023. Report a data issue: hello@regdatalab.com.